Therese Standal

Summary

Affiliation: Norwegian University of Science and Technology
Country: Norway

Publications

  1. ncbi request reprint HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma
    Therese Standal
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 109:3024-30. 2007
  2. ncbi request reprint Role of osteopontin in adhesion, migration, cell survival and bone remodeling
    Therese Standal
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Exp Oncol 26:179-84. 2004
  3. doi request reprint Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro
    Sofia Jonsson
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    J Bone Miner Metab 30:119-23. 2012
  4. ncbi request reprint Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
    Therese Standal
    Institute of Cancer Research and Molecular Biology, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 100:3925-9. 2002
  5. doi request reprint CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and in vitro osteoblastogenesis
    Nikolai N Nørgaard
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    J Immunol 185:3131-9. 2010
  6. doi request reprint Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis
    Berit Grandaunet
    Norwegian University of Science and Technology, Trondheim, Norway
    Arthritis Rheum 63:662-9. 2011
  7. ncbi request reprint Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma
    Therese Standal
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Haematologica 89:174-82. 2004
  8. ncbi request reprint Bone disease in multiple myeloma
    Øyvind Hjertner
    Department of Haematology, St Olav University Hospital, Institute of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology N 7006 Trondheim, Norway
    Med Oncol 23:431-41. 2006
  9. pmc PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
    Anne Marit Sponaas
    KG Jebsen Centre for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    PLoS ONE 10:e0139867. 2015
  10. ncbi request reprint Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells
    Therese Standal
    Institute of Cancer Research and Molecular Biology, Faculty of Medicine, Norwegian University of Science and Technology, Medisinsk Teknisk Senter, Trondheim, Norway
    Blood 100:3002-7. 2002

Collaborators

Detail Information

Publications14

  1. ncbi request reprint HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma
    Therese Standal
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 109:3024-30. 2007
    ..45, P = .008), in sera from 34 patients with myeloma. These observations suggest that HGF inhibits bone formation in multiple myeloma...
  2. ncbi request reprint Role of osteopontin in adhesion, migration, cell survival and bone remodeling
    Therese Standal
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Exp Oncol 26:179-84. 2004
    ..In this review focus will be on OPN in bone and its role in adhesion, migration and cell survival. These aspects of OPN biology are important in tumorigenesis...
  3. doi request reprint Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro
    Sofia Jonsson
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    J Bone Miner Metab 30:119-23. 2012
    ..This finding might partly explain why previous studies on the effects of imatinib osteoblast differentiation have shown different results...
  4. ncbi request reprint Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
    Therese Standal
    Institute of Cancer Research and Molecular Biology, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 100:3925-9. 2002
    ..In the patient group with IGF-1 levels above 13 nM, median survival was 62 months (P =.006). These findings support the hypothesis of a role for IGF-1 in myeloma disease progression...
  5. doi request reprint CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and in vitro osteoblastogenesis
    Nikolai N Nørgaard
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    J Immunol 185:3131-9. 2010
    ..In conclusion, our results demonstrate that PTO-CpG-ODN inhibits BMP-signaling, and thus might provoke unwanted TLR9-independent side effects in patients...
  6. doi request reprint Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis
    Berit Grandaunet
    Norwegian University of Science and Technology, Trondheim, Norway
    Arthritis Rheum 63:662-9. 2011
    ..The present study was thus undertaken to investigate whether plasma levels of HGF and Dkk-1 are related to bone damage in patients with rheumatoid arthritis (RA)...
  7. ncbi request reprint Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma
    Therese Standal
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Haematologica 89:174-82. 2004
    ..It is involved in a number of physiologic and pathologic events including adhesion, angiogenesis, apoptosis, inflammation, wound healing and tumor metastasis. We wanted to investigate the potential role of OPN in multiple myeloma...
  8. ncbi request reprint Bone disease in multiple myeloma
    Øyvind Hjertner
    Department of Haematology, St Olav University Hospital, Institute of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology N 7006 Trondheim, Norway
    Med Oncol 23:431-41. 2006
    ..Bisphosphonates are the only drugs used in routine clinical management; however, the complex regulation system of bone homeostasis offers a number of of possible targets for therapy, which are discussed...
  9. pmc PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
    Anne Marit Sponaas
    KG Jebsen Centre for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    PLoS ONE 10:e0139867. 2015
    ..A correlation between the proportion of PDL1+ PC and CD141+ mDC was found, suggesting both cell types could down-regulate the anti-tumor T cell response. ..
  10. ncbi request reprint Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells
    Therese Standal
    Institute of Cancer Research and Molecular Biology, Faculty of Medicine, Norwegian University of Science and Technology, Medisinsk Teknisk Senter, Trondheim, Norway
    Blood 100:3002-7. 2002
    ..The results suggest a novel biologic mechanism for the bone disease associated with MM and that treatment of the bone disease with OPG lacking the heparin-binding domain should be considered...
  11. doi request reprint Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment
    Tobias Schmidt Slørdahl
    The KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Eur J Haematol 91:399-410. 2013
    ..Nanobodies are therapeutic proteins based on the smallest functional fragments of heavy-chain-only antibodies. In this study, we wanted to determine the anticancer effect of a novel anti-c-MET Nanobody in MM...
  12. doi request reprint High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients
    Anne K Mylin
    Department of Haematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
    Eur J Haematol 80:310-7. 2008
    ..Here, the association between serum YKL-40 and severity of bone disease in MM is investigated...
  13. ncbi request reprint Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival
    Niels Frost Andersen
    Department of Haematology, Aarhus University Hospital, Aarhus Hospital, Aarhus, Denmark
    Br J Haematol 128:210-7. 2005
    ....
  14. ncbi request reprint Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy
    Carina Seidel
    Department of IMPI, Division of Pathology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Br J Haematol 119:672-6. 2002
    ..005). Our results show that in young myeloma patients HGF is elevated, and that patients with higher levels had a trend towards poorer prognosis. Treatment with high-dose chemotherapy reduced HGF in the serum of the majority of patients...